ASLAN Pharmaceuticals Limited
NASDAQ: ASLN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carl Alan Jason Morton Firth EMBA,
- Employees
- 35
- Headquarters
- Singapore, Singapore
- IPO year
- 2018
- Market cap
- $777.1M
- Website
- https://aslanpharma.com
Loading ASLN…
Loading profile data…Frequently asked questions about ASLN
What does ASLAN Pharmaceuticals Limited (ASLN) do?
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range...
Where does ASLN trade?
ASLAN Pharmaceuticals Limited (ASLN) trades on the NASDAQ Global Market.
What sector is ASLN in?
ASLAN Pharmaceuticals Limited (ASLN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ASLAN Pharmaceuticals Limited?
Carl Alan Jason Morton Firth EMBA, is the chief executive officer of ASLAN Pharmaceuticals Limited (ASLN).
Where is ASLAN Pharmaceuticals Limited headquartered?
ASLAN Pharmaceuticals Limited is headquartered in Singapore.
Does ASLN pay a dividend?
ASLAN Pharmaceuticals Limited (ASLN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ASLN go public?
ASLAN Pharmaceuticals Limited (ASLN) completed its initial public offering in 2018.
Is ASLN an ADR?
Yes — ASLN is an American Depositary Receipt; its underlying shares trade on a non-US exchange. ASLAN Pharmaceuticals Limited reporting and dividends follow the underlying issuer.